Achilles Therapeutics plc (ACHL)

NASDAQ: ACHL · IEX Real-Time Price · USD
0.948
+0.010 (1.03%)
At close: May 17, 2024, 4:00 PM
0.960
+0.012 (1.29%)
After-hours: May 17, 2024, 7:49 PM EDT
1.03%
Market Cap 38.40M
Revenue (ttm) n/a
Net Income (ttm) -64.43M
Shares Out 41.09M
EPS (ttm) -1.60
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 114,355
Open 0.927
Previous Close 0.938
Day's Range 0.903 - 0.960
52-Week Range 0.740 - 1.760
Beta 1.25
Analysts Hold
Price Target 2.83 (+198.59%)
Earnings Date May 8, 2024

About ACHL

Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic o... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Mar 31, 2021
Employees 204
Stock Exchange NASDAQ
Ticker Symbol ACHL
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for ACHL stock is "Hold." The 12-month stock price forecast is $2.83, which is an increase of 198.59% from the latest price.

Price Target
$2.83
(198.59% upside)
Analyst Consensus: Hold
Stock Forecasts

News

Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Achilles ADSs will continue to trade on the Nasdaq Global Select Market at this time, and the Company's operations are not affected by the receipt of the Notice Achilles ADSs will continue to trade on...

1 day ago - GlobeNewsWire

Achilles Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

– Provided interim Phase I/IIa update on clonal neoantigen reactive T cells in advanced NSCLC and melanoma – – Evaluating the benefit of enhanced host conditioning with further data expected in 2H 202...

10 days ago - GlobeNewsWire

Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights

– Provided interim Phase I/IIa update on clonal neoantigen reactive T cells in advanced NSCLC and melanoma – – Improved VELOS™ manufacturing process delivering higher cNeT doses – – Protocols updated ...

6 weeks ago - GlobeNewsWire

Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning

– Improved VELOS™ manufacturing process delivering higher cNeT doses – – Protocols updated to evaluate the benefit of enhanced host conditioning, with further data expected in 2H 2024 – – First three ...

6 weeks ago - GlobeNewsWire

Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference

LONDON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoanti...

3 months ago - GlobeNewsWire

Achilles Therapeutics Announces Publication of Nature Cancer ‘Comment' on Strategy for Improved Neoantigen Immunogenicity Prediction

Newly developed computational tools and large datasets with low bias will lead to robust neoantigen prediction and improved personalized cancer therapies Newly developed computational tools and large ...

5 months ago - GlobeNewsWire

Achilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights

– On track to dose 15-20 patients with higher dose cNeT by year-end 2023 – – Clinical and translational science data update from the ongoing Phase I/IIa trials in NSCLC and melanoma expected in Q1 202...

6 months ago - GlobeNewsWire

Achilles Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

- Clinical and translational science data expected in the fourth quarter of 2023 from the ongoing Phase I/IIa trials in NSCLC and melanoma -

10 months ago - GlobeNewsWire

Achilles Therapeutics to Present at Upcoming Conferences

LONDON, June 12, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors, t...

1 year ago - GlobeNewsWire

Achilles Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights

- Phase I/IIa clinical trials in NSCLC and melanoma progressing with additional clinical and translational science data expected in the fourth quarter of 2023 -

1 year ago - GlobeNewsWire

Achilles Therapeutics' New Immunogenicity Prediction Application of its AI-Powered PELEUS™ Platform Uniquely Identifies the Most Potent T Cell Antigens

- New AI module delivers a "Target-to-T cell” approach for revolutionizing the identification and prioritization of targets for personalized antigen approaches - - New AI module delivers a "Target-to-...

1 year ago - GlobeNewsWire

Achilles Therapeutics Announces Grant of US Patent Covering the Treatment of Patients with an Immunotherapy Targeting Neoantigens Based on Tumor HLA Status

- Patent broadly covers technology to select neoantigens that are presented by HLA molecules determined to be present in a patient's tumor -

1 year ago - GlobeNewsWire

Achilles Therapeutics to Present at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

LONDON, April 17, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors, ...

1 year ago - GlobeNewsWire

Achilles Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Business Highlights

- Demonstrated early proof-of-concept for cNeT therapy in heavily pre-treated advanced NSCLC patients -

1 year ago - GlobeNewsWire

Achilles Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

LONDON, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors, t...

1 year ago - GlobeNewsWire

Achilles Therapeutics Presents Encouraging Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma at ESMO IO Congress 2022

- Early proof-of-concept data support durable clinical benefit including confirmed partial response and stable disease in heavily pre-treated patients with advanced NSCLC -

1 year ago - GlobeNewsWire

Achilles Therapeutics to Present Early Proof of Concept of Safety and Clinical Activity of Clonal Neoantigen Reactive T Cells at the ESMO Immuno-Oncology Annual Congress 2022

- Durable partial response (PR) and stable disease (SD) achieved in heavily pre-treated non-small cell lung cancer (NSCLC) patients dosed with cNeT monotherapy -

1 year ago - GlobeNewsWire

Achilles Therapeutics Announces Grant of US Patent on Immunotherapies Targeting Clonal Neoantigens Identified Using Proprietary Method

- US patent is for an immunotherapy targeting clonal neoantigens identified by the Achilles Clonality Engine (ACE), including vaccine, antibody, and autologous T cell therapy approaches - - US patent ...

1 year ago - GlobeNewsWire

Achilles Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights

- Interim update from the ongoing Phase I/IIa trials in advanced NSCLC (CHIRON) and melanoma (THETIS) to be presented at the ESMO Immuno-Oncology Annual Congress 2022 -

1 year ago - GlobeNewsWire

Achilles Therapeutics Co-founder Professor Charles Swanton to Participate in Expert Roundtable Highlighting Pivotal Nature of Neoantigens as Targets in Cancer Cell Therapy

Professor Swanton joins Achilles SAB member Dr. Christopher Klebanoff and Dr. John Haanen on the key opinion leader panel to discuss neoantigens as valuable immunotherapy targets

1 year ago - GlobeNewsWire

Achilles Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights

- Additional clinical data from the ongoing Phase I/IIa trials in advanced NSCLC (CHIRON) and melanoma (THETIS) expected to be available in Q4 2022 -

1 year ago - GlobeNewsWire

Achilles Therapeutics to lead Horizon Europe-Funded Consortium to Advance Personalized Cell Therapy Manufacturing

€4 million ($4.2 million) research and innovation award for consortium to develop first-in-class smart bioprocessing manufacturing platform €4 million ($4.2 million) research and innovation award for ...

1 year ago - GlobeNewsWire

Achilles Therapeutics Appoints James Taylor as Chief Business Officer and Cassian Yee, MD to Scientific Advisory Board

LONDON, June 30, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announ...

2 years ago - GlobeNewsWire

Achilles Therapeutics Recognized with the 2022 PING Innovation Award

LONDON, June 21, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announ...

2 years ago - GlobeNewsWire

Achilles Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights

- Dosed first patient with higher-dose (Process 2) cNeT for advanced NSCLC (CHIRON) and initiated enrollment of cNeT + PD-1 inhibitor combination (THETIS Cohort B) for metastatic malignant melanoma -

2 years ago - GlobeNewsWire